Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-05-29
2007-05-29
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C435S320100
Reexamination Certificate
active
08278601
ABSTRACT:
A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
REFERENCES:
patent: 4554159 (1985-11-01), Roizman et al.
patent: 4769331 (1988-09-01), Roizman et al.
patent: 4859587 (1989-08-01), Roizman
patent: 5288641 (1994-02-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5658724 (1997-08-01), DeLuca
patent: 5665362 (1997-09-01), Inglis et al.
patent: 5804413 (1998-09-01), DeLuca
patent: 5837261 (1998-11-01), Inglis et al.
patent: 5879934 (1999-03-01), DeLuca
patent: 6541009 (2003-04-01), Inglis et al.
patent: 0213894 (1986-08-01), None
patent: 0277773 (1988-01-01), None
patent: 0386882 (1990-02-01), None
patent: 0453242 (1991-04-01), None
patent: 89/09271 (1989-10-01), None
patent: 90/05538 (1990-05-01), None
patent: 91/05055 (1991-04-01), None
patent: 92/05263 (1992-04-01), None
patent: WO94/01573 (1994-01-01), None
patent: WO94/03207 (1994-02-01), None
patent: WO94/03595 (1994-02-01), None
patent: WO94/21807 (1994-09-01), None
McCarthy et al. J. Virol. 63(1): 18-27 Jan. 1989.
Bostock (Vet. Microbiol. 23:55-71, Jun. 1990). Abstract only cited.
Bostock (Vet. Microbiol. 23:55-71, Jun. 1990).
Dobson et al (Neuron 5:353-60, 1990).
Cartwright (TIBTECH 5:25-30, 1987).
Katz et al (Journal of Virology 64:4288-4295, 1990).
Shih, Meng-Fu et al., “Expression of hepatitis B virusSgene by herpes simplex virus type 1 vectors carrying α- and β-regulated gene chimeras,”Proc. Natl. Acad. Sci. USA,81:5867-5870, (1984).
Coutelier, Jean-Paul et al., “IgG2a restriction of murine antibodies elicited by viral infections,”J. Exp. Med.,165:64-69 (1987).
Coutelier, Jean-Paul et al., Brief Definitive Report, “Virally induced modulation of murine IgG antibody subclasses,”J. Exp. Med.,166:2373-2378 (1988).
Nguyen, Lien H. et al., “Replication-Defective Mutants of Herpes Simplex Virus (HSV) Induce Cellular Immunity and Protect against Lethal HSV Infection,”J. Virol.,66(12) :7067-7072 (1992).
Kipps, Thomas J. et al., “Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies,”J. Exp. Med.,161:1-17 (1985).
Gao, Min and Knipe,, David M., “Genetic Evidence for Multiple Nuclear Functions of the Herpes Simplex Virus ICP8 DNA-Binding Protein,”Journal of Virology,63(12):5258-5267, (1989).
Cunningham, Charles et al., “The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel virus-induced protein kinase,”Journal of General Virology,73:303-311, (1992).
Stevenson, David et al., “Characterization of the varicella-zoster virus gene 61 protein,”Journal of General Virology,73:521-530, (1992).
Ali, Mir A. et al., “Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunite from herpes simplex virus type 2,”Proc. Natl. Acad. Sci. USA,88:8257-8261, (1991).
Rice, Stephen A. and Knipe, David M., “Genetic Evidence for Two Distinct Transactivation Functions of the Herpes Simplex Virus α Protein ICP27,”J. Virol.,64:1704-1715, (1990).
Rice, Stephen A. et al., “Herpes Simplex Virus Alpha Protein ICP27 Possesses Separable Positive and Negative Regulatory Activities,”J. Virol.,63:3399-3407, (1989).
“Fowlpox Virus: A ‘Live-Dead’ Vaccine Vector,”ASM News,58 (5):257, (1992).
Quinn, John P. and McGeoch, Duncan J., “DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein,”Nucleic Acids Research,13(22):8143-8163, (1985).
Sacks, Wendy R. et al., “Herpes Simplex Virus Type 1 ICP27 Is an Essential Regulatory Protein,”J. Virol.,55(3):796-805, (1985).
Baer, R. et al., “DNA sequence and expression of the B95-8 Epstein-Barr virus genome,”Nature,310:207-211, (1984).
Galloway, Denise A. et al., “Small fragments of herpesvirus DNA with Transforming activity contain insertion sequence-like structures,”Proc. Natl. Acad. Sci. USA,81:4736-4740, (1984).
Weller, Sandra K. et al., “Genetic Analysis of Temperature-Sensitive Mutants Which Define the Gene for the Major Herpes Simplex Virus Type 1 DNA-Binding Protein,”J. Virol.,45(1):354-366, (1983).
Farrell, H. et al., “Vaccine potential of a herpes simplex virus mutant lacking an essential glycoprotein,” Abstract,17th International Herpesvirus Workshop, Edinburgh, Scotland, p. 378, (Aug. 1-7, 1992).
McLean, L. et al., “Protective vaccination with a gH-deleted HSV-1 virus,”18th International Herpesvirus Workshop,Pittsburgh, PA, p. C-71, (Jul. 25-30, 1993).
DeLuca, Neal A. et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4,”J. Virol.,56(2):558-570, (1985).
Emi, Nobuhiko et al., “Pseudotype Formation of Murine Leukemia Virus with the G Protein of Vesicular Stomatitis Virus,”J. Virol.,65(3): 1202-1207, (1991).
Jayaraman, Sundararajan et al., “Exacerbation of Murine Herpes Simplex Virus-Mediated Stromal Keratitis by Th2 Type T Cells,”Journal of Immunology,151(10):5777-5789, (1993).
Marchetti, Michael E. et al., “A Temperature-Sensitive Mutation in a Herpes Simplex Virus Type 1 Gene Required for Viral DNA Synthesis Maps to Coordinates 0.609 through 0.614 in UL,”J. Virol.,62(3):715-721, (1988).
Ligas, Michael W. and Johnson, David C., “A Herpes Simplex Virus Mutant in Which Glycoprotein D Sequences Are Replaced by β-Galactosidase Sequences Binds to but Is Unable to Penetrate into Cells,”J. Virol.,62(5):1486-1494, (1988).
Farrell, H. E. et al., “Vaccine Potential of a Herpes Simplex Virus Type 1 Mutant with an Essential Glycoprotein Deleted,”J. Virology,68(2):927-932, (1994).
Morrison, Lynda A. and Knipe, David M., “Immunization with Replication-Defective Mutants of Herpes Simplex Virus Type 1: Sites of Immune Intervention in Pathogenesis of Challenge Virus Infection,”J. Virol.68:689-696 (1994).
Nguyen, Lien et al., “Mechanism of Virus-Induced Ig subclass Shifts,”J. Immunol.152:478-484 (1994).
Robertson, L.M., et al., “Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716,”Journal of General Virology,73:967-970(1992).
Finberg Robert
Knipe David
Siber George
Dana-Farber Cancer Institute
Neuner George W.
President & Fellows of Harvard College
Salimi Ali R.
LandOfFree
Herpesvirus replication defective mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpesvirus replication defective mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpesvirus replication defective mutants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785229